GW-1100 is a selective GPR40 (FFAR1) antagonist used to inhibit GPR40-mediated intracellular calcium elevations induced by agonists such as GW9508, oleic acid, and linoleic acid; it is employed in vitro to study GPR40 signaling in CHO-K1/bFFAR1 cells and neutrophils, and in vivo to block the antinociceptive effects of GPR40 agonists like GW9508 and DHA in models of inflammatory pain (e.g., CFA-induced mechanical allodynia and thermal hyperalgesia).